SOPH SOPHiA GENETICS SA
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimoda…
Industry Peers
Health Information Services| Headline | Source | Time |
|---|---|---|
Older | ||
 SOPHiA GENETICS (SOPH) Moves 7.0% Higher: Will This Strength Last? SOPHiA GENETICS (SOPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. | ||
 SOPHiA GENETICS (SOPH) Stock Sees Modest Fair Value Lift After Q2 Guidance Raise SOPHiA GENETICS is back in focus as analysts reset their central price views, with fair value moving from US$9.00 to US$9.75. Recent research linking the company’s role in data driven oncology and rare disease diagnostics with Q2 results and higher guidance has supported price targets in a US$9 to US$12 range, while still flagging execution and valuation risk. Read on to see how these shifting targets feed into the broader SOPHiA GENETICS story and how you can track the narrative from... | ||
 When Unusual Volume Isn't Noise: 3 Small-Caps Sending Signals Canada Goose, Capital Clean Energy Carriers and SOPHiA Genetics have each seen unusual trading volume recently, driven by tariffs, LNG demand, and a strong earnings beat, respectively. | ||
 SOPHiA GENETICS (SOPH) Q2 2026 Earnings Call Transcript Revenue jumped 27% as platform volume surged and biopharma partnerships accelerated. | ||
 AstraZeneca (LSE:AZN) Signs Two Cancer Diagnostics Deals To Widen Patient Access SOPHiA GENETICS and AstraZeneca (LSE:AZN) have entered a global partnership to develop and launch two decentralized companion diagnostics in precision oncology. The multi-year collaboration focuses on clinical trial assays that support development and commercialization of AstraZeneca's oncology therapies. The partners aim to expand access to personalized cancer treatments by enabling decentralized testing across a wider range of clinical settings. For readers tracking how data driven tools... | ||
 SOPHiA GENETICS partners with AstraZeneca for oncology diagnostics SOPHiA GENETICS is tasked with developing its Solid Tumor application as a decentralised companion diagnostic. | ||
Sophia Genetics SA (SOPH) (Q2 2026) Earnings Call Highlights: Record Revenue Growth and ... Sophia Genetics SA (SOPH) delivers 27% revenue growth, raises full-year guidance, and announces landmark AstraZeneca CDX deals and MSK joint venture. | ||
 SOPHiA GENETICS Q2 Earnings Call Highlights SOPHiA GENETICS (NASDAQ:SOPH) reported second-quarter revenue growth of 27% and raised its full-year revenue outlook, as the precision medicine software company cited accelerating U.S. adoption, liquid biopsy momentum and new biopharma agreements. Revenue for the second quarter totaled $23.3 millio | ||
 SOPH Stock Heads For Best Day In Over 8 Months – What’s Driving Today’s Super Rally? Sophia Genetics announced a partnership with AstraZeneca to develop two cancer diagnostic tests and also raised its full-year revenue forecast. | ||